# Health Sciences Fund

Health Sciences Fund is a registered fund series of John Hancock Funds II (series S000034046). Net assets $94.5M as of 2025-02-28.

## Profile

- Series ID: S000034046
- Registrant: John Hancock Funds II
- LEI: 549300UTX0DZQILK4I63
- Net assets: $94.5M
- Total assets: $95.0M
- As of: 2025-02-28

## Advisers

- [T. Rowe Price Associates, Inc. (Subadvisor)](https://search.stillhousedata.com/firm/105496)
- [John Hancock Investment Management LLC (Advisor)](https://search.stillhousedata.com/firm/105790)

## Top holdings (169 reported)

_Showing 15 of 169 holdings by value._

| Holding | Ticker | Value | % of fund |
| --- | --- | --- | --- |
| [Eli Lilly and Company](https://search.stillhousedata.com/security/532457108) | — | $10.6M | 1119.36% |
| [Intuitive Surgical Inc.](https://search.stillhousedata.com/security/46120E602) | — | $5.9M | 623.87% |
| [UnitedHealth Group Incorporated](https://search.stillhousedata.com/security/91324P102) | — | $5.2M | 547.79% |
| [Thermo Fisher Scientific Inc.](https://search.stillhousedata.com/security/883556102) | — | $4.5M | 470.79% |
| [Stryker Corporation](https://search.stillhousedata.com/security/863667101) | — | $4.2M | 444.84% |
| [argenx SE](https://search.stillhousedata.com/security/04016X101) | — | $3.5M | 368.29% |
| [Vertex Pharmaceuticals Incorporated](https://search.stillhousedata.com/security/92532F100) | — | $3.0M | 317.39% |
| [Boston Scientific Corporation](https://search.stillhousedata.com/security/101137107) | — | $3.0M | 313.66% |
| [Danaher Corporation](https://search.stillhousedata.com/security/235851102) | — | $2.7M | 286.79% |
| [Alnylam Pharmaceuticals Inc.](https://search.stillhousedata.com/security/02043Q107) | — | $2.3M | 243.58% |
| [AstraZeneca PLC](https://search.stillhousedata.com/security/046353108) | — | $2.2M | 230.60% |
| [Elevance Health Inc.](https://search.stillhousedata.com/security/036752103) | — | $1.7M | 184.87% |
| [Regeneron Pharmaceuticals Inc.](https://search.stillhousedata.com/security/75886F107) | — | $1.6M | 168.54% |
| [Insmed Incorporated](https://search.stillhousedata.com/security/457669307) | — | $1.6M | 164.78% |
| [BeiGene Ltd.](https://search.stillhousedata.com/security/07725L102) | — | $1.5M | 162.55% |

## Net asset history

| Report date | Net assets |
| --- | --- |
| 2025-02-28 | $94.5M |
| 2024-11-30 | $227.1M |
| 2024-08-31 | $234.8M |
| 2024-05-31 | $268.1M |
| 2024-02-29 | $270.8M |
| 2023-11-30 | $255.4M |
| 2023-08-31 | $265.4M |
| 2023-05-31 | $304.0M |

## More

- [Registrant: John Hancock Funds II](https://search.stillhousedata.com/registrant/1331971)
- [This page as markdown (for LLM agents)](https://search.stillhousedata.com/fund/S000034046.md)
- [Search all SEC filings, advisers and people on Adviser Search](https://search.stillhousedata.com/)

---

Source: public SEC filing data via Adviser Search (https://search.stillhousedata.com).
Agents: this data is also queryable via MCP tools and read-only SQL — see https://search.stillhousedata.com/llms.txt.